Navigation Links
Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive,Heart Failure Presented at Late-Breaking Session of Heart Failure,Congress 2007

iuretics; and -- the absence of treatment failure. Treatment failure was defined as: -- death; -- readmission to the hospital for heart failure within seven days of the first dose of KW-3902 or placebo; -- worsening of heart failure; or -- worsening renal function.

Patients treated with 30 milligrams of KW-3902 showed higher rates of treatment success and lower rates of treatment failure compared to the placebo group.

The pilot study also showed that 24-hours after treatment, self-reported marked or moderate improvement in dyspnea was observed in 66 percent of the patients who received the 30 milligram dose of KW-3902 as compared to 51 percent in the placebo group.

There were no statistical differences or trends in adverse events observed in the pilot study. The results of the study confirmed that 30 milligrams of KW-3902 is an appropriate dose for NovaCardia's two 600-patient pivotal Phase 3 trials, PROTECT 1 and PROTECT 2, which are currently enrolling participants in the United States, Canada, Europe, Israel and Russia.

KW-3902 is believed to block adenosine-mediated constriction of blood flow to the kidneys and inhibit reabsorption of salt and water by the kidney, thereby increasing urine volume and maintaining renal function in patients with CHF. As renal function deteriorates in patients with CHF, higher doses of diuretics are required in order to reduce fluid overload.

Multiple studies have demonstrated that renal dysfunction is a strong independent predictor of worse short- and long-term outcomes in patients with CHF. In the NovaCardia pilot study, the 30 milligram dose of KW-3902 also showed a positive effect on patients' renal function over time compared to placebo. Although KW-3902 was administered for only the first three days of the trial, an apparent dose response was seen in serum creatinine, a commonly used marker of worsening renal function, at day 14. The study showed no
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:1/15/2014)... January 15, 2014 Shire plc (LSE: SHP, NASDAQ: ... of Fair Trading (OFT) approval condition to the announced tender offer ...   As a result of the waiver, the transaction ... complete the tender offer on January 24, 2014 following the currently ...
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
(Date:1/15/2014)... 2014 The Cadence Fitness & Health Center has ... Medical Fitness Association, a non-profit organization assisting medically integrated ... The Cadence Fitness & Health Center is the only ... in the Chicagoland area. "The certification means ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
... MEDomics, LLC provides NextGen sequence-based DNA diagnostic ... era and is transforming diagnostic testing for mitochondrial ... capital investment from our partner, SpaGus Ventures LLC. ... used by MEDomics to fuel the continued growth ...
... FLORHAM PARK, N.J., April 7, 2011 Shionogi Inc., ... today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) ... reduce chronic severe drooling in patients aged 3 to ... as cerebral palsy. "Shionogi is proud ...
Cached Medicine Technology:MEDomics Announces a Growth Capital Investment from SpaGus Ventures LLC and Gary Augusta Joins MEDomics as Chief Operating Officer 2Shionogi Announces Commercial Availability of CUVPOSA™ (Glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated With Neurologic Conditions 2Shionogi Announces Commercial Availability of CUVPOSA™ (Glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated With Neurologic Conditions 3Shionogi Announces Commercial Availability of CUVPOSA™ (Glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated With Neurologic Conditions 4Shionogi Announces Commercial Availability of CUVPOSA™ (Glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated With Neurologic Conditions 5
(Date:4/24/2014)... at the University of York reveals that a process ... the nervous system may also play a pivotal role ... team, led by Dr Will Brackenbury, a Medical Research ... has studied how voltage-gated sodium channels assist in the ... the membranes of excitable cells, such as neurons, where ...
(Date:4/23/2014)... stool from healthy, unrelated donors was safe and ... caused by Clostridium difficile , according to ... Infectious Diseases and available online. Known as ... whether given via a colonoscope or a nasogastric ... this promising treatment more readily available to patients. ...
(Date:4/23/2014)... researchers say clinical trials for a new experimental ... very promising. Patients treated with CPX-351, a combination ... showing better responses than patients treated with the ... myeloid leukemia is an aggressive blood cancer with ... older patients," explained Jeffrey Lancet, M.D., senior member ...
(Date:4/23/2014)... M.D., scientific director at the National Institute of Arthritis ... the 2014 recipient of the Ross Prize in Molecular ... Molecular Medicine . The award will be given ... Sciences in Manhattan, followed by scientific presentations by Dr. ... the National Institutes of Health. , The award, which ...
(Date:4/23/2014)... 2014 The American Society for Radiation Oncology (ASTRO) ... Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO ... radiation therapy in the treatment of endometrial cancer. ... May-June 2014 issue of Practical Radiation Oncology ... ASTRO. The full-length guideline is available as an ...
Breaking Medicine News(10 mins):Health News:Breast cancer replicates brain development process 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3
... To reduce mortality and improve patient care in the ... Care Societies Collaborative (CCSC), in conjunction with the US ... that research in the field become less fragmented and ... critical illness. The CCSC comprises the ...
... a popular activity in nursing homes, senior centers ... beyond socializing. Researchers found high-contrast, large bingo cards ... cognitive difficulties and visual perception problems produced by ... "The general finding of improved performance across healthy ...
... Michigan State University researchers one working at a medieval ... in East Lansing have shown how modern science can ... the first to confirm the existence of brucellosis, an infectious ... The findings, which appear in the American Journal of ...
... best cigarette is no cigarette, but for the millions ... researchers from Cornell University may have found a way ... antioxidant extracts in cigarette filters, the researchers were able ... reduced the amount of cancer-causing free radicals passing through ...
... suggests that there may be a positive relationship between ... to a report in the January issue of ... the JAMA/Archives journals. Amika Singh, Ph.D., of the ... and Care Research, Amsterdam, the Netherlands, and colleagues reviewed ...
... , SUNDAY, Jan. 1 (HealthDay News) -- Losing weight is ... long-held behaviors is a skill in itself, a medical expert ... people have to be ready to face some setbacks and ... and medical weight-loss specialist at Gottlieb Memorial Hospital, part of ...
Cached Medicine News:Health News:ATS issues joint statement on key issues and recommendations for critical care research 2Health News:ATS issues joint statement on key issues and recommendations for critical care research 3Health News:'BINGO!' game helps researchers study perception deficits 2Health News:Scientists crack medieval bone code 2Health News:Physical activity, school performance may be linked 2Health News:Persistence Is Key to Losing Weight and Keeping It Off 2Health News:Persistence Is Key to Losing Weight and Keeping It Off 3
... The Vitros ECi brings true ... to immunodiagnostic testing. Highly sensitive assays ... oncology and bone metabolism testing are ... under development. The Vitros ECi can ...
... is a flexible system that ... environments small hospitals, backup ... satellite locations. The Vitros 250 ... can be automated or placed ...
... an effort to improve on the ... toxicology, abused drugs, and immunosuppressants tests, ... which incorporates random access capabilities. Although ... undergone several important changes in the ...
The IMx system is an automated analyzer designed to perform microparticle enzyme immunoassay (MEIA), fluorescence polarization immunoassay (FPIA) and ion capture technologies....
Medicine Products: